BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34246177)

  • 21. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
    Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
    Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
    [No Abstract]   [Full Text] [Related]  

  • 22. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients.
    Lau HD; Chan E; Fan AC; Kunder CA; Williamson SR; Zhou M; Idrees MT; Maclean FM; Gill AJ; Kao CS
    Am J Surg Pathol; 2020 Jan; 44(1):98-110. PubMed ID: 31524643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [FH-deficient renal cell carcinoma expands the spectrum of renal papillary tumors].
    Rupp N; Moch H
    Pathologe; 2021 Nov; 42(6):560-564. PubMed ID: 34448900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal cell carcinoma with angioleiomyoma-like stroma and clear cell papillary renal cell carcinoma: exploring SDHB protein immunohistochemistry and the relationship to tuberous sclerosis complex.
    Williamson SR; Hornick JL; Eble JN; Gupta NS; Rogers CG; True L; Grignon DJ; Cheng L
    Hum Pathol; 2018 May; 75():10-15. PubMed ID: 29180251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The MIB-1 tumor proliferation index in adult renal epithelial tumors with granular cytoplasm: biologic implications and differential diagnostic potential.
    Tickoo SK; Amin MB; Linden MD; Zarbo RJ
    Mod Pathol; 1998 Nov; 11(11):1115-21. PubMed ID: 9831210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AKR1B10 Is a New Sensitive and Specific Marker for Fumarate Hydratase-Deficient Renal Cell Carcinoma.
    Zheng L; Zhang X; Pan X; Huang Z; Zhang M; Xian J; Wei Y; Nie L; Zhang M; Gong J; Chen X; Zhou Q; Zeng H; Chen N
    Mod Pathol; 2023 Nov; 36(11):100303. PubMed ID: 37580017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
    Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
    Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas.
    Yoo A; Tang C; Zucker M; Fitzgerald K; DiNatale RG; Rappold PM; Weiss K; Freeman B; Lee CH; Schultz N; Motzer R; Russo P; Coleman J; Reuter VE; Chen YB; Carlo MI; Gill AJ; Kotecha RR; Ari Hakimi A; Reznik E
    Eur Urol Focus; 2022 Sep; 8(5):1278-1288. PubMed ID: 35288096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture.
    Michalova K; Tretiakova M; Pivovarcikova K; Alaghehbandan R; Perez Montiel D; Ulamec M; Osunkoya A; Trpkov K; Yuan G; Grossmann P; Sperga M; Ferak I; Rogala J; Mareckova J; Pitra T; Kolar J; Michal M; Hes O
    Ann Diagn Pathol; 2020 Feb; 44():151448. PubMed ID: 31918172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma].
    Yu YF; He SM; Wu YC; Xiong SW; Shen Q; Li YY; Yang F; He Q; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):640-646. PubMed ID: 34393221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases.
    Pan X; Zhang M; Yao J; Zeng H; Nie L; Gong J; Chen X; Xu M; Zhou Q; Chen N
    J Clin Pathol; 2019 Nov; 72(11):748-754. PubMed ID: 31262952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
    Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
    Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of the Na+/K+-transporting ATPase gamma subunit FXYD2 in renal tumors.
    Gaut JP; Crimmins DL; Lockwood CM; McQuillan JJ; Ladenson JH
    Mod Pathol; 2013 May; 26(5):716-24. PubMed ID: 23196795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma.
    Williamson SR; Eble JN; Amin MB; Gupta NS; Smith SC; Sholl LM; Montironi R; Hirsch MS; Hornick JL
    Mod Pathol; 2015 Jan; 28(1):80-94. PubMed ID: 25034258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemistry for 2-Succinocysteine (2SC) and Fumarate Hydratase (FH) in Cutaneous Leiomyomas May Aid in Identification of Patients With HLRCC (Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome).
    Buelow B; Cohen J; Nagymanyoki Z; Frizzell N; Joseph NM; McCalmont T; Garg K
    Am J Surg Pathol; 2016 Jul; 40(7):982-8. PubMed ID: 26945337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single nucleotide variants of succinate dehydrogenase A gene in renal cell carcinoma.
    Kamai T; Higashi S; Murakami S; Arai K; Namatame T; Kijima T; Abe H; Jamiyan T; Ishida K; Shirataki H; Yoshida KI
    Cancer Sci; 2021 Aug; 112(8):3375-3387. PubMed ID: 34014604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Claudin-7 immunohistochemistry in renal tumors: a candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling.
    Hornsby CD; Cohen C; Amin MB; Picken MM; Lawson D; Yin-Goen Q; Young AN
    Arch Pathol Lab Med; 2007 Oct; 131(10):1541-6. PubMed ID: 17922590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can renal oncocytoma be differentiated from its renal mimics? The utility of anti-mitochondrial, caveolin 1, CD63 and cytokeratin 14 antibodies in the differential diagnosis.
    Mete O; Kilicaslan I; Gulluoglu MG; Uysal V
    Virchows Arch; 2005 Dec; 447(6):938-46. PubMed ID: 16133362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detailed Morphologic and Immunohistochemical Characterization of Myomectomy and Hysterectomy Specimens From Women With Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC).
    Chan E; Rabban JT; Mak J; Zaloudek C; Garg K
    Am J Surg Pathol; 2019 Sep; 43(9):1170-1179. PubMed ID: 31162287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients.
    Fuchs TL; Maclean F; Turchini J; Vargas AC; Bhattarai S; Agaimy A; Hartmann A; Kao CS; Ellis C; Bonert M; Leroy X; Kunju LP; Schwartz L; Matsika A; Williamson SR; Rao P; Divatia M; Guarch R; Algaba F; Balancin ML; Zhou M; Samaratunga H; da Cunha IW; Brimo F; Ryan A; Clouston D; Aron M; O'Donnell M; Chan E; Hirsch MS; Moch H; Pang CY; Wah C; Yin W; Perry-Keene J; Yilmaz A; Chou A; Clarkson A; van der Westhuizen G; Morrison E; Zwi J; Hes O; Trpkov K; Gill AJ
    Mod Pathol; 2022 Jun; 35(6):836-849. PubMed ID: 34949766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.